BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/10/2017 5:31:06 AM | Browse: 358 | Download: 594
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Study |
Article Title |
Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Joshua C Berkowitz, Joanna Stein-Fishbein, Sundas Khan, Richard Furie and Keith S Sultan |
Funding Agency and Grant Number |
|
Corresponding Author |
Keith S Sultan, MD, Assistant Professor, Hofstra Northwell School of Medicine, 300 Community Dr., Manhasset, NY 11030, United States. ksultan@northwell.edu |
Key Words |
Crohn’s disease; Ulcerative colitis; Infliximab; Azathioprine; Inflammatory bowel disease |
Core Tip |
In our 13 year experience at a community hospital infusion center, approximately 26% of inflammatory bowel disease patients receiving infliximab infusions received concomitant immunomodulator therapy. This is comparable to rates of combination therapy (CT) at major tertiary referral centers. However, there was a trend of decreased utilization of CT over the study period, even following the publication of SONIC. This suggests a need for further study to define the population with the most favorable risk-benefit ratio from CT, as well as the need for more direct guidelines from major societies. |
Citation |
Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS. Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. World J Gastrointest Pharmacol Ther 2018; 9(1): 8-13 |
|
Received |
|
2017-03-21 09:13 |
|
Peer-Review Started |
|
2017-03-23 16:51 |
|
To Make the First Decision |
|
2017-05-03 14:52 |
|
Return for Revision |
|
2017-05-08 20:10 |
|
Revised |
|
2017-06-12 14:19 |
|
Second Decision |
|
2017-11-06 01:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-11-10 05:31 |
|
Articles in Press |
|
2017-11-10 05:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-01-25 09:28 |
ISSN |
2150-5349 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345